Defeating glioblastoma multiforme will take full-force effort

Alfred Yung

With limited treatment options and no cure, brain cancer is one of the science and medical world's hardest nuts to crack.

The most common and deadliest form of brain cancer is glioblastoma multiforme, or GBM for short. This particular cancer has for decades resisted the efforts of the best in the biomedical research community, who are always looking for better treatment options for patients.

These efforts include the National Institutes of Health's The Cancer Genome Atlas (TCGA) project, which in 2006 chose GBM as the first tumor to sequence and analyze to better understand the disease. The brain tumor community's successful push to make GBM one of the main focuses of the TCGA was due in large part to the unfortunate fact that there has been little progress in the fight against this tumor over the past three decades; a result of the complexity and aggressiveness of this particular form of brain cancer.

GBM tumors are highly heterogeneous with multiple subtypes, and often a multitude of different mutations and cell types within a single tumor. In addition, the cancerous cells frequently invade other healthy tissue throughout the brain, further illustrating their aggressive nature. Consequently, survival statistics for this patient population are staggeringly low.

And, while the TCGA GBM project netted volumes of important information and data, the big payout for patient care that is desperately needed has yet to materialize.

As a long-time strategic adviser to the National Brain Tumor Society, I joined the organization's executive team, program staff and board of directors, along with other strategic, scientific and medical peers to analyze the current landscape and pinpoint why progress was not happening despite this attention. As a result of these discussions, National Brain Tumor Society created the Defeat GBM Research Collaborative earlier this year.

Defeat GBM is a strategic research initiative, created as a subsidiary of the National Brain Tumor Society, and aims to double the five-year survival rate of GBM patients in five years. To achieve this goal, the initiative will connect leading brain tumor researchers from top cancer institutions, including MD Anderson Cancer Center, Ludwig Institute for Cancer Research and Memorial Sloan-Kettering Cancer Center, in a full-force effort to significantly impact patients through better collaboration, data sharing and a unique scientific plan designed to speed progress.

I was honored to be selected as the scientific director of this initiative to lead a Strategic Scientific Advisory Council (SSAC), comprised of many of the top minds in brain cancer research. Together we will oversee this effort, including charting the direction of Defeat GBM research, reviewing project progress, as well as ensuring investigator teams are working in synergy and achieving key milestones and annual goals.

Talk about this article with other patients, caregivers, and advocates in the General Discussions CURE discussion group.
Special Feature
Share Your Art
Related Articles
BRCA Mutations May Cause Drug Resistance in Breast and Ovarian Cancer
There is a relationship between the genetics of BRCA1 and BRCA2 mutations and the risk of a patient with breast or ovarian cancer being resistant to platinum-based chemotherapy, according to recent research conducted at the Perelman School of Medicine at the University of Pennsylvania. The study’s senior author Katherine Nathanson, M.D., spoke with CURE about these findings.
Sarah Sciortino on Fertility and Sexuality in Younger Patients with Ovarian Cancer
Sarah Sciortino, MSW, LSW, Oncology Psychosocial Support Services Program Coordinator at University of Chicago Hospital, discusses the unique concerns that younger patients with ovarian cancer can face.
Caring With Confidence: Study Examines Caregiver Mastery and Patient Survival in GBM
A recent study found that the level of family caregiver mastery may have an effect on the survival of patients with glioblastoma.
Related Videos
Examining Quality of Life Issues for Patients With MPNs
Sandra Allen-Bard, MSN, ANCC, AOCNP, of Weill Cornell Medical Center, discusses the impact myeloproliferative neoplasms can have on patients' quality of life.
Elliott Winton on the Changing Landscape of MPN Treatment
Elliott Winton, M.D., researcher, physician and 2016 MPN Hero, discusses some of the drastic changes that happened over the past decade or so in the world of MPNs. 
Siddhartha Mukherjee on Increasing MPN Awareness
Siddhartha Mukherjee, M.D., Ph.D, an oncologist, researcher and Pulitzer Prize-winning science writer, discusses the increasing awareness about myeloproliferative neoplasms (MPNs).
//For side ad protocol